It is because of the significant role of PTP1B in cancer that a PTP1B inhibitor—MSI-1436C, a potential drug for diabetes, was previously tested in a phase I clinical trial for the treatment of metastatic breast cancer12. Here, PTPN1 is linked to diabetes mellitus.